6.47MMarket Cap-305P/E (TTM)
1.0200High0.9900Low149.48KVolume1.0200Open1.0200Pre Close149.95KTurnover2.38%Turnover RatioLossP/E (Static)6.41MShares4.169952wk High1.10P/B6.35MFloat Cap0.765052wk Low--Dividend TTM6.29MShs Float236.0000Historical High--Div YieldTTM2.94%Amplitude0.7650Historical Low1.0030Avg Price1Lot Size
Adial Pharmaceuticals Stock Forum
EXCLUSIVE: Adial Pharmaceuticals Tells Benzinga 'Marks Final Study Needed for the Upcoming FDA Meeting for the Phase 3 Study Design and Ongoing Partnership Discussions'
GLEN ALLEN, Va., Oct. 23, 2024 — Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that it will be participating in The ThinkEquity Conference on October 30, 2024, at the Mandarin Oriental Hotel i...
Adial Pharmaceuticals Announces Database Lock in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder
Larger Image: tradingview.com...
$Adial Pharmaceuticals (ADIL.US)$
Adial Pharmaceuticals (NASDAQ: ADIL) has announced the completion of patient dosing in the pharmacokinetics study of AD04, their lead investigational treatment for Alcohol Use Disorder (AUD). The study, involving 30 healthy adult volunteers, aims to optimize dosing and enhance efficacy and safety for AUD patients. Topline results are expected in the fourth quarter of 2024.
The single-center open-label study compares the pharmacokinetic profile of AD04 at a 0.33 ...
No comment yet